CancerDrs

Prostate Cancer clinical trials in Massachusetts

44 actively recruiting prostate cancer trials at 12 sites across Massachusetts.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Massachusetts:
  • Brigham and Women's Hospital — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
  • Dana-Farber/Brigham and Women's Cancer Center at Milford Regional — Milford, Massachusetts
  • Dana-Farber/Brigham and Women's Cancer Center at South Shore — South Weymouth, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Massachusetts:
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Sites in Massachusetts:
  • Dana Farber Cancer Institute — Boston, Massachusetts
  • Beth Israel Deaconess Medical Center — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Federal

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…

Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Massachusetts:
  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)

This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid prescribing following routine robotic-assisted laparoscopic prostatectomy (RALP). Patients…

Sponsor: Brigham and Women's Hospital
NCT ID: NCT07427043
Sites in Massachusetts:
  • Brigham and Women's Hospital — Boston, Massachusetts
  • Brigham and Women's Faulkner Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Massachusetts:
  • Lahey Clinic — Burlington, Massachusetts
  • Lahey Clinic Peabody — Peabody, Massachusetts
  • Mercy Medical Center — Springfield, Massachusetts
  • Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care — Winchester, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Massachusetts:
  • Massachusetts General Hospital (MGH) — Boston, Massachusetts
  • Dana Farber Cancer Institute (HARVARD) — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abir…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06991556
Sites in Massachusetts:
  • Mass General Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in Massachusetts:
  • Research Site — Boston, Massachusetts
  • Research Site — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…

Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Massachusetts:
  • Research Site — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of HLD-0915 in Patients With Metastatic Prostate Cancer

Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06800313
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of A…

Sponsor: AstraZeneca
NCT ID: NCT07336446
Sites in Massachusetts:
  • Research Site — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombi…

Sponsor: Prostate Cancer Clinical Trials Consortium
NCT ID: NCT06844383
Sites in Massachusetts:
  • Dana Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 …

Sponsor: AstraZeneca
NCT ID: NCT07192614
Sites in Massachusetts:
  • Research Site — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high…

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT04363164
Sites in Massachusetts:
  • Dana-Faber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing h…

Sponsor: University of British Columbia
NCT ID: NCT04812366
Sites in Massachusetts:
  • Dana-Farber Cancer Institute / Beth Israel Deaconess Medical Center — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special type of diagnostic imaging done during…

Sponsor: Martin T. King, MD, PhD
NCT ID: NCT07393867
Sites in Massachusetts:
  • Brigham and Women's Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
  • Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center — Milford, Massachusetts
  • Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital — Weymouth, Massachusetts
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cell…

Sponsor: Weill Medical College of Cornell University
NCT ID: NCT04946370
Sites in Massachusetts:
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy. The main questions it aims to answer are: * Does fezolinetant impro…

Sponsor: Shehzad Basaria, M.D.
NCT ID: NCT06957691
Sites in Massachusetts:
  • Brigham and Women's Hospital — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…

Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Massachusetts:
  • Exelixis Clinical Site #7 — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…

Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Massachusetts:
  • Brigham and Women's Hospital — Boston, Massachusetts
  • Dana Farber Cancer Institute — Boston, Massachusetts
  • Dana Farber Cancer Institute- Chestnut Hill — Newton, Massachusetts
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…

Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Massachusetts:
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Sponsor: SystImmune Inc.
NCT ID: NCT05983432
Sites in Massachusetts:
  • Massachusetts General Hospital — Boston, Massachusetts
  • Dana-Farber Cancer Institute — Boston, Massachusetts
View on ClinicalTrials.gov →

Showing 25 of 44 trials with sites in Massachusetts. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17